Literature DB >> 19675187

Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain.

Barbara Marchetti1, Elisabeth A Gault1, Marc S Cortese1, ZhengQiang Yuan1, Shirley A Ellis2, Lubna Nasir1, M Saveria Campo1.   

Abstract

Bovine papillomavirus type 1 is one of the aetiological agents of equine sarcoids. The viral major oncoprotein E5 is expressed in virtually all sarcoids, sarcoid cell lines and in vitro-transformed equine fibroblasts. To ascertain whether E5 behaves in equine cells as it does in bovine cells, we introduced the E5 open reading frame into fetal equine fibroblasts (EqPalF). As observed in primary bovine fibroblasts (BoPalF), E5 by itself could not immortalize EqPalF and an immortalizing gene, such as human telomerase (hTERT/hT), was required for the cells to survive selection. The EqPalF-hT-1E5 cells were morphologically transformed, elongated with many pseudopodia and capable of forming foci. Equine major histocompatibility complex class I (MHC I) was inhibited in these cells at least at two levels: transcription of MHC I heavy chain was inhibited and the MHC I complex was retained in the Golgi apparatus and prevented from reaching the cell surface. We conclude that, as in bovine cells and tumours, E5 is a player in the transformation of equine cells and the induction of sarcoids, and a potential major cause of MHC I downregulation and hence poor immune clearance of tumour cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19675187     DOI: 10.1099/vir.0.014746-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours.

Authors:  Lies Bogaert; Andrew W Woodham; Diane M Da Silva; Ann Martens; Evelyne Meyer; W Martin Kast
Journal:  J Gen Virol       Date:  2015-06-04       Impact factor: 3.891

2.  Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses.

Authors:  E K Hainisch; S Brandt; S Shafti-Keramat; R Van den Hoven; R Kirnbauer
Journal:  Equine Vet J       Date:  2011-09-06       Impact factor: 2.888

3.  Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation.

Authors:  Bettina Hartl; Edmund K Hainisch; Saeed Shafti-Keramat; Reinhard Kirnbauer; Annunziata Corteggio; Giuseppe Borzacchiello; Reinhard Tober; Christina Kainzbauer; Barbara Pratscher; Sabine Brandt
Journal:  J Gen Virol       Date:  2011-06-29       Impact factor: 3.891

4.  Both tumour cells and infiltrating T-cells in equine sarcoids express FOXP3 associated with an immune-supressed cytokine microenvironment.

Authors:  A Douglas Wilson; Chelsea Hicks
Journal:  Vet Res       Date:  2016-05-09       Impact factor: 3.683

5.  Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.

Authors:  Christoph Jindra; Edmund K Hainisch; Andrea Rümmele; Markus Wolschek; Thomas Muster; Sabine Brandt
Journal:  PLoS One       Date:  2021-11-19       Impact factor: 3.240

6.  Equine sarcoids: Bovine Papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53.

Authors:  Margaret Finlay; Zhengqiang Yuan; Iain M Morgan; M Saveria Campo; Lubna Nasir
Journal:  Vet Res       Date:  2012-12-04       Impact factor: 3.683

7.  IFN-τ Mediated Control of Bovine Major Histocompatibility Complex Class I Expression and Function via the Regulation of bta-miR-148b/152 in Bovine Endometrial Epithelial Cells.

Authors:  Haichong Wu; Kangfeng Jiang; Shuai Guo; Jing Yang; Gan Zhao; Changwei Qiu; Ganzhen Deng
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.